{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=17", "query": { "intervention": "Placebo Intravenous", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 2347, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T08:03:29.191Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03466411", "title": "A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Guselkumab Dose 1", "type": "DRUG" }, { "name": "Guselkumab Dose 2", "type": "DRUG" }, { "name": "Guselkumab Dose 3", "type": "DRUG" }, { "name": "Guselkumab Dose 4", "type": "DRUG" }, { "name": "Guselkumab Dose 5", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1409, "start_date": "2018-04-13", "completion_date": "2028-01-28", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 109, "location_summary": "Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03466411" }, { "nct_id": "NCT01941511", "title": "A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Rivipansel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlycoMimetics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2013-08", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2020-06-18", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941511" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" }, { "nct_id": "NCT03027609", "title": "Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pseudomonas Aeruginosa Pneumonia" ], "interventions": [ { "name": "AR-105", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aridis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2017-03-29", "completion_date": "2019-04-25", "has_results": true, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 14, "location_summary": "Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03027609" }, { "nct_id": "NCT01335932", "title": "Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Respiratory Failure" ], "interventions": [ { "name": "IV Ganciclovir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2011-03-10", "completion_date": "2016-10-28", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 14, "location_summary": "Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335932" }, { "nct_id": "NCT02548494", "title": "Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 1", "Diabetic Ketoacidosis" ], "interventions": [ { "name": "Glargine", "type": "DRUG" }, { "name": "IV insulin", "type": "DRUG" }, { "name": "Electrolyte Correction", "type": "OTHER" }, { "name": "Correction of Fluid Loss", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Chattanooga-Hamilton County Hospital Authority", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 17, "start_date": "2015-11", "completion_date": "2019-02-01", "has_results": false, "last_update_posted_date": "2020-09-23", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 1, "location_summary": "Chattanooga, Tennessee", "locations": [ { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548494" }, { "nct_id": "NCT05764707", "title": "Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Treatment in Spinal Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lumbar; Injury" ], "interventions": [ { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-01-10", "completion_date": "2023-02-03", "has_results": false, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05764707" }, { "nct_id": "NCT02467075", "title": "Double-Blind Placebo-Controlled CIN Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Kidney Injury" ], "interventions": [ { "name": "Iopamidol 300 (Contrast)", "type": "DRUG" }, { "name": "Placebo (Normal Saline)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02467075" }, { "nct_id": "NCT03654729", "title": "Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer", "Chemotherapy-induced Peripheral Neuropathy" ], "interventions": [ { "name": "Calmangafodipir (2 µmol/kg)", "type": "DRUG" }, { "name": "Calmangafodipir (5 µmol/kg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Egetis Therapeutics AB (publ)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2018-11-07", "completion_date": "2020-08-31", "has_results": true, "last_update_posted_date": "2021-12-17", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 11, "location_summary": "Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654729" }, { "nct_id": "NCT02358681", "title": "Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Ketorolac, intranasal", "type": "DRUG" }, { "name": "Ketorolac, intravenous", "type": "DRUG" }, { "name": "Placebo, intravenous", "type": "DRUG" }, { "name": "Placebo, intranasal", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 59, "start_date": "2015-06-16", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-10-14T08:03:29.191Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358681" } ] }